Cancer Biomarkers Market is expected to worth USD 27.4 billion by 2024


Posted May 22, 2017 by ravikantdubey

Databridgemarketresearch.com presents “Cancer Biomarkers Market is expected to worth USD 27.4 billion by 2024”, also states in North America, Europe, Asia-Pacific, South America, Rest of the World.

 
Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024.

The Global Cancer Biomarkers Market has accounted to USD 10.9 billion in 2016, growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4 billion by 2024.

Based on type, the Global Cancer Biomarkers Market is broadly split into three segments, namely, protein biomarkers, genetic biomarkers, and other biomarkers (includes viral, cell, and carbohydrate biomarkers). The increasing focus of pharmaceutical companies towards the discovery of protein biomarkers is further expected to fuel the growth of this market in the coming years. However, the genetic biomarkers segment is expected to grow at the highest CAGR during the forecast period.

On the basis of cancer type, the Global Cancer Biomarkers Market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancers (includes melanoma, leukemia, gastric, kidney, liver, and pancreatic cancers).

The Global Cancer Biomarkers Market, by profiling technology, is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics.

Request for sample pages: http://databridgemarketresearch.com/reports/global-cancer-biomarkers-market/

Based on geography the global cancer biomarkers market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Read more: http://databridgemarketresearch.com/global-cancer-biomarkers-market-expected-reach-usd-21-8/

Some of the major players operating in this market are Abbott Laboratories, DiagnoCure Inc., Affymetrix, Inc., Illumina, Inc., Qiagen N.V., Roche Diagnostics Ltd., Agilent Technologies Inc., Quest Diagnostics Inc., Merck & Co. Inc., Hologic, Inc., Becton Dickinson and Company among others.

About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Data Bridge Market Research
Website Global Cancer Biomarkers Market – Industry Trends and Forecast to 2024
Phone +1-888-387-2818
Business Address Amanora Chambers, Magarpatta Road, Hadapsar
Pune – 411028, Maharashtra
Country India
Categories Health , Manufacturing , Medical
Tags biomarkers , cancer biomarkers market , global cancer biomarkers market
Last Updated May 22, 2017